drugset / Trial / NCT04895917
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This study aims at establishing a new powerful combination of daratumumab and pomalidomide as rescue treatment for patients with R/R AL amyloidosis.
Timeline
- Start
- 2021-06-23
- Primary completion
- 2024-12-18
- Completion
- 2025-01-15
Outcome
Outcome not reported
Stopped (Enrollment): “low patient enrollment rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |